Sanara MedTech (SMTI) Q4 2024 earnings summary

Executive summary

• Net revenue for 2024 reached $86.7 million, up 33% year-over-year, with Q4 revenue rising 49% to $26.3 million, driven by strong soft tissue product sales and growth in bone fusion products.

• Achieved positive Adjusted EBITDA of $2.7 million for the year and $0.9 million in Q4, with significant profitability gains in the Sanara Surgical segment.

• Q4 net loss widened to $1.7 million; full-year net loss increased to $9.9 million, reflecting higher R&D and SG&A investments.

• Expanded commercial reach to over 350 distributor partners and more than 1,300 facilities by year-end.

• Advanced the Tissue Health Plus (THP) segment with clinical model development, technology platform, and preparation for a 2025 pilot launch.

Financial highlights

• Soft tissue product sales grew 39% to $76.1 million; bone fusion products rose 6% to $10.5 million year-over-year.

• Q4 gross profit increased 51% to $24.1 million, with gross margin rising to 91.4%.

• Operating expenses for Q4 increased 51% to $24.4 million, mainly from higher SG&A and R&D.

• As of December 31, 2024: $15.9 million in cash, $30.5 million in principal debt, and $24.5 million in available borrowing capacity.

• Net loss per share for 2024 was $1.14, compared to $0.52 in 2023.

Outlook and guidance

• Plans to further expand sales coverage and surgeon adoption in 2025, with new clinical manuscripts expected.

• THP segment to launch its first pilot with a wound care provider group in Q2 2025 and a payer pilot in the second half.

• Continued investment in THP expected at $7.5–$10 million in the first half of 2025, with pursuit of financial partners to offset spending.

• Confident in capital resources to support strategic growth initiatives.

• Focus on driving revenue growth and profitability in the Sanara Surgical segment in 2025.